News

A United States patent entitled "Erythrocytes Containing Arginine Deiminase" has been issued by the U.S. Patent and Trademark Office (USPTO) as U.S. Patent No. 9,125,876. It covers the

Keryx carried out a phase 2, non-dialysis study and a 58-week, phase 3 registration trial on about 1900 patients. The company said in the phase 3 trial, ferric

Enrolment in the clinical trial is expected to commence in the next few weeks. In its planned Phase 1/2 clinical trial, ESSA intends to demonstrate the safety, tolerability,

The survey was conducted online by Harris Poll on behalf of the CHPA Educational Foundation in February 2015 among 2,002 U.S. adults 18 and older who have used

Under the study, Amgen and Allergan evaluated the efficacy and safety of ABP 215 compared with Genentech’s Avastin (bevacizumab) in patients with advanced non-small cell lung cancer. The

The company started enrolling patients in IFN-K-002 double-blind, randomized, placebo-controlled, multi-center study to identify the biological and clinical efficacy of IFNa-Kinoid in patients suffering from SLE. Neovacs intends

Edoxaban is an oral, once-daily, direct factor Xa inhibitor, which is one of the key parts responsible for blood clotting. Under the ENGAGE AF-TIMI 48 global phase 3

Pfizer secured a license for the contraceptive, allowing women to inject themselves at home rather than going to clinic or GP surgery. Sayana Press combines a long-acting, reversible,

CVS/pharmacy has expanded the availability of the opioid overdose reversal medicine, naloxone, in several states. The medication was already available at CVS/pharmacy without a prescription in Rhode Island